A minimally invasive outpatient procedure may help people avoid weight rebound after stopping popular drugs like Ozempic and semaglutide, according to a study presented at Digestive Disease Week® (DDW) 2026. About 70% of people who stop taking these drugs eventually regain much of the weight they lost, often within 18 months. Nearly one in five obese adults uses glucagon-like peptide-1 (GLP-1), highlighting the scale of this challenge.
Researchers report the first blinded, randomized, sham-controlled evidence that a procedure called duodenal mucosal resurfacing may provide a safe and durable way to maintain weight loss without continuing medication. The study results suggest that it may help patients maintain the benefits they gained while taking drugs such as Ozempic and other GLP-1 therapies.
“GLP-1 drugs are effective, but many people stop taking them because of cost, side effects, or simply because they don’t want to take them long-term,” said lead author Shelby Sullivan, M.D., director of the Endoscopic Obesity and Metabolism Program at the Dartmouth Center for Healthy Weight and Professor of Medicine at Dartmouth Geisel School of Medicine. “However, when these drugs are discontinued, the majority of patients regain weight and lose metabolic benefit. Finding a treatment that allows patients to discontinue these drugs without gaining weight or losing metabolic benefit remains a major unmet need. These findings demonstrate that this minimally invasive procedure may enable maintenance of sustained weight loss.”
How the “gut reset” procedure works
Duodenal mucosal resurfacing is an investigational endoscopic treatment that uses controlled heat to remove damaged tissue from the lining of the duodenum, the first part of the small intestine just below the stomach. This process excises (burns) the unhealthy mucosal layer and promotes the growth of new, healthier tissue.
The ongoing REMAIN-1 trial aims to test whether this regeneration of the intestinal lining causes a permanent metabolic reset, allowing the body to maintain weight loss after stopping drugs such as semaglutide and tirzepatide.
Test results show less weight gain
The current findings come from an initial group of participants with 6 months of follow-up data. Of the 45 people in this cohort, 29 received resurfacing treatment and 16 received sham treatment. All participants had lost at least 15% of their body weight using tirzepatide before stopping the drug.
On average, patients lost about 40 pounds while receiving GLP-1 therapy. Six months after drug discontinuation, the control group gained significantly more weight. Participants who received the sham treatment regained about 40% more weight than those who received the real treatment.
Additionally, patients who underwent more extensive resurfacing gained back only about 7 pounds and maintained more than 80 percent of the weight they lost. By comparison, the control group recovered approximately twice as much. The difference between the two groups continued to widen from 1 to 6 months post-procedure, suggesting that the effect persists and may become even stronger over time.
“What’s particularly encouraging is that its effects appear to increase rather than wane over time, and it acts like a drug in terms of a dose response,” Dr. Sullivan said. “This gives us confidence that we are targeting the right biology.”
Safety and recovery
No serious complications were reported from either the device or the procedure. Recovery is relatively quick, with most patients returning to normal activities within about a day.
“Other than recovering from general anesthesia, recovery doesn’t take long,” Dr. Sullivan says. “People can return to their daily activities in about a day. Participants didn’t know whether they had a fake or real surgery because they didn’t have many symptoms after the surgery.”
Why the gut is key to weight regulation
This treatment targets the small intestine, where many of the hormones affected by GLP-1 drugs are produced. A diet high in fat and sugar can change the lining of the duodenum over time, changing the way your body processes food and regulates hormones. These changes can lead to insulin resistance and metabolic diseases.
This procedure aims to reset how the body responds to food by restoring a healthier mucosal layer, which can help stabilize your metabolism at a lower weight after discontinuing drugs like Ozempic.
what happens next
Duodenal mucosal resurfacing is still considered to be under investigation. The large REMAIN-1 study includes over 300 participants and is fully enrolled and randomized. The researchers expect to release six months of topline data from the key cohort in early Q4 2026, followed by a planned marketing submission later that year.
Dr. Sullivan will present the study results in “Resurfacing Duodenal Mucosa Impairs Weight Recovery After Tirzepatide Withdrawal: REMAIN-1 Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial — Results from the Midpoint Cohort,” Abstract 642, CDT, Monday, May 4, at 8:30 a.m.
